Sunday, November 8, 2026

GBP/EUR Bullish Momentum With A 1% Jump In The Last 5 Sessions

ViaNews Editorial Team

August 16, 2023

GBP/EUR Bullish Momentum With A 1% Jump In The Last 5 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.32% for the last 5 sessions. At 11:07 EST on Wednesday, 16 August, GBP/EUR (GBPEUR) is $1.17.

GBP/EUR's yearly highs and lows, it's 8.092% up from its 52-week low and 1.946% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy hits fresh YTD top around 145.20, lacks follow-through amid intervention fears. According to FXStreet on Monday, 14 August, "The USD/JPY pair kicks off the new week on a positive note and touches a fresh YTD peak during the Asian session. ", "This marks a big divergence in comparison to a more dovish stance adopted by the Bank of Japan (BoJ), which is the only central bank in the world to maintain a negative benchmark interest rate, and suggests that the path of least resistance for the USD/JPY pair remains to the upside."
  • Japan Q2 GDP improves to 1.5% qoq versus 0.8% expected and 0.7% prior, usd/jpy slides below 145.50. According to FXStreet on Tuesday, 15 August, "Following the data, USD/JPY refreshed intraday low to 145.37, around 145.45 by the press time, while extending the late Monday's U-turn from the highest level since November 2022, as well as probing the five-day uptrend."
  • Usd/jpy grinds at yearly top around 145.00 as boj intervention, sluggish yields test bulls. According to FXStreet on Monday, 14 August, "A 100-pip area within a three-week-old rising triangle formation, currently between 145.40 and 144.40, prods the USD/JPY buyers amid overbought RSI (14) conditions.", "Looking ahead, inflation clues from Japan will join the US Retail Sales and Fed Minutes to direct the short-term USD/JPY moves. "
  • Usd/jpy closed above 145.00 ahead of Japanese GDP data. According to FXStreet on Monday, 14 August, "At the start of the week, the USD/JPY rose to its highest level since November 10, 2022, mainly driven by a cautious market mood and a stronger USD. ", "The daily chart analysis indicates a bullish outlook for the USD/JPY in the short term. "
  • Usd/jpy holds below the 145.00 area as boj offers unlimited jgbs at fixed-rate. According to FXStreet on Monday, 14 August, "In the absence of the top-tier economic data release from Japan this week, market players will focus on US Retail Sales, FOMC Minutes and the comment from the Fed official to take cues and find a clear direction in the USD/JPY pair. ", "Following the data, USD/JPY reaches a new intraday low near 144.65 and posts its first loss in six days after reaching a new yearly high earlier in the day."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com